Trial Information

Summary: A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme

Status: No longer recruiting

Protocol Number: BO17884

Sponsor: F Hoffmann -La Roche Ltd/ Inc/AG

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of Tarceva and either temozolomide or BCNU on progression-free survival in patients with recurrent glioblastoma multiforme

Brief Summary: This study will assess the efficacy and safety of Tarceva compared to that of one of 2 comparator drugs (depending on pre-treatment of patients) in patients with recurrent glioblastoma multiforme. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals. Target sample size is 110.

Study Phase: II

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Randomized
  • Masking: Open Label
  • Control: Active
  • Assignment: Parallel
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Glioblastoma multiforme

Intervention Type: Drug

Intervention Name: erlotinib[Tarceva]

Primary Outcome: 1. Progression-free survival probability at 6 months

Key Secondary Outcomes: 1. Response rate and duration of response; acute side effects; and overall survival

Inclusion Criteria:

  • adult patients >18 years of age;
  • glioblastoma multiforme;
  • recurrent disease documented by MRI after previous radiation therapy;
  • stable or decreasing dose of corticosteroids for >=2 weeks before treatment initiation;
  • Karnofsky performance status >=70.

Exclusion Criteria:

  • previous treatment for recurrent disease;
  • >1 previous chemotherapy regimen given as adjuvant treatment;
  • previous treatment with her-targeted agents or experimental therapies;
  • previous irradiation to the brain within 3 months of randomization;
  • concomitant treatment with anticoagulants.

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: July, 2004

Trial Registration Date: 06/24/2005

Date Last Updated: 06/17/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Villejuif, France, 94804
Telephone: 973-235-5000 or 800-526-6367

  

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 30, 2008 at 3:14:47 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA